cdmo.directory
← Compare landing

Samsung Biologics vs WuXi XDC

Side-by-side profile data from each company listing. Missing fields stay blank rather than filled with assumptions.

CategorySamsung BiologicsWuXi XDC
SummaryLeading CDMO offering end-to-end biologics development and manufacturing from cell line development through aseptic fill-finish, with capabilities in drug substance, drug product, ADC, and mRNA services.WuXi XDC is a leading CRDMO offering integrated discovery, development, and cGMP manufacturing services for antibody drug conjugates (ADCs) and bioconjugates, with proximately located facilities that reduce development timelines and costs.
Services
  • Biologics Development & Manufacturing
  • Monoclonal Antibody (mAb) Manufacturing
  • Recombinant Protein Manufacturing
  • Cell-Line Development
  • Upstream Processing
  • Downstream Processing
  • ADC (Antibody-Drug Conjugate) Manufacturing
  • ADC Payload & Linker Synthesis
  • mRNA Manufacturing
  • Lipid Nanoparticle (LNP) Formulation
  • Vaccine Manufacturing
  • Sterile Fill-Finish & Aseptic Manufacturing
  • Vial Filling
  • Prefilled Syringe (PFS) Filling
  • Cartridge Filling
  • Lyophilization (Freeze Drying)
  • Process Development
  • Formulation Development
  • Technology Transfer
  • CMC Analytical Development
  • Quality Control Testing
  • Stability Testing & Storage
  • CMC Regulatory Submission Support
  • Monoclonal Antibody (mAb) Manufacturing
  • Recombinant Protein Manufacturing
  • ADC (Antibody-Drug Conjugate) Manufacturing
  • ADC Payload & Linker Synthesis
  • Bioconjugation Services
  • Sterile Fill-Finish & Aseptic Manufacturing
  • Vial Filling
  • Lyophilization (Freeze Drying)
  • Process Development
  • Formulation Development
  • Technology Transfer
  • CMC Analytical Development
Modalities
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Antibody-Drug Conjugate (ADC)
  • mRNA
  • Vaccine
  • Biologics (Monoclonal Antibodies)
  • Antibody-Drug Conjugate (ADC)
Development capabilities
  • Analytical method development
  • Formulation development
  • ICH stability testing
  • Cell line development
  • Analytical method development
  • Formulation development
Manufacturing capabilities
  • Drug Substance (DS)
  • Drug Product (DP)
  • Liquid Vials
  • Lyophilized Vials
  • Prefilled Syringes (PFS)
  • Cartridges
  • Max bioreactor: Large commercial (≤10,000 L)
  • Expression: Mammalian
  • Expression: Cell-Free
  • Single-Use / Disposable
  • Stainless Steel
  • Drug Substance (DS)
  • Drug Product (DP)
  • Liquid Vials
  • Lyophilized Vials
  • Expression: Mammalian
Locations
  • Bio Campus I, South Korea
  • Bio Campus II, South Korea
  • Headquarters / Bio Campus I, Incheon, Yeonsu-gu, Republic of Korea
  • Bio Campus II, Incheon, Yeonsu-gu, Republic of Korea
  • ADC Plant, Incheon, Yeonsu-gu, Republic of Korea
  • Samsung Biologics America, United States
  • Samsung Biologics Japan Office, Japan
  • Headquarters
  • Headquarters, China
  • Singapore Site, Singapore, Singapore
CertificationsData not yet provided.Data not yet provided.

Find similar companies

Samsung Biologics alternatives · WuXi XDC alternatives

Markdown mirror: /compare/samsungbiologics/wuxi-xdc.md